APA (7th ed.) Citation

Kristensen, L. E., Keiserman, M., Papp, K., McCasland, L., White, D., Carter, K., . . . Behrens, F. (2024). Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial. Rheumatology & Therapy, 11(3), 617. https://doi.org/10.1007/s40744-024-00654-5

Chicago Style (17th ed.) Citation

Kristensen, Lars Erik, et al. "Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial." Rheumatology & Therapy 11, no. 3 (2024): 617. https://doi.org/10.1007/s40744-024-00654-5.

MLA (9th ed.) Citation

Kristensen, Lars Erik, et al. "Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial." Rheumatology & Therapy, vol. 11, no. 3, 2024, p. 617, https://doi.org/10.1007/s40744-024-00654-5.